Study details
Enrolling now
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
Luminary Therapeutics
NCT IDNCT06340750ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
18
Study length
about 1.2 years
Ages
18–65
Locations
1 site in OH
What this study is about
This trial is testing the safety and recommended dose of BAFF CAR-T cells (LMY-920) in adults with severe lupus. The goal is to determine if this treatment can improve lupus symptoms.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive LMY-920
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Recommended Phase 2 Dose (RP2D)
Body systems
Immune